BCMA+CD38 AND BCMA+GPRC5D
DUAL CAR-T FOR MYELOMA
When BCMA disappears from myeloma cells, single-target CAR-T becomes ineffective. Dual-target constructs ensure there is always a second way in.
analyticsAt a Glance
- check_circleBCMA antigen loss or downregulation drives relapse in 20–30% of myeloma patients after BCMA-directed therapy
- check_circleBCMA+CD38 and BCMA+GPRC5D dual-target CAR-T constructs are in active clinical development at Chinese centres
- check_circleEarly Chinese data shows dual-target products achieving sCR rates of 70–85% with potentially lower antigen-escape relapse
- check_circleCancerFax identifies eligibility for dual-target myeloma trials and coordinates access for international patients
The BCMA Antigen Loss Problem in Myeloma CAR-T
BCMA-directed CAR-T produces the deepest remissions of any therapy in multiple myeloma — but relapse still occurs in a significant proportion of patients, and when it does after BCMA-directed therapy, BCMA expression on relapsing plasma cells is often reduced or absent. This 'antigen escape' — the same mechanism responsible for CD19-loss relapse in ALL — is driving the development of dual-target myeloma CAR-T constructs that attack myeloma cells through two independent pathways simultaneously.
“Myeloma cells are molecular escape artists. Dual-target therapy blocks two exit routes instead of one — making escape dramatically harder to achieve.”
BCMA+CD38: Two Targets Already Used in Myeloma
CD38 is already a validated myeloma target — daratumumab (anti-CD38 monoclonal antibody) is standard first-line myeloma therapy. Combining BCMA and CD38 in a single CAR-T construct covers two independently expressed myeloma antigens, requiring simultaneous loss of both to escape — while also leveraging the known anti-myeloma activity of CD38 targeting.
BCMA+GPRC5D: Sequential Target After BCMA Failure
GPRC5D is expressed independently of BCMA on myeloma plasma cells — and critically, its expression is often maintained or even upregulated when BCMA is lost. A BCMA+GPRC5D dual construct addresses both the primary myeloma disease and the BCMA-loss escape variant simultaneously, rather than requiring sequential single-target treatments.
Dual-Target Myeloma CAR-T: Key Numbers from Early Chinese Data
Published and presented data from Chinese academic centres developing dual-target myeloma CAR-T constructs.
- 20–30%BCMA expression loss or significant downregulation after BCMA-directed CAR-T or bispecific therapyThe frequency of BCMA antigen escape in myeloma patients relapsing after BCMA-directed therapy — the primary problem dual-target constructs are designed to solve.
- 82–90%ORR with BCMA+GPRC5D dual-target CAR-T in early Chinese seriesEarly data from Chinese trials of BCMA+GPRC5D dual-target constructs show ORR of 82–90% — including in patients who have previously received BCMA monotherapy.
- ~70%sCR rate in BCMA+CD38 dual-target early Chinese cohort dataBCMA+CD38 dual-target series from Chinese academic centres report stringent complete remission rates of approximately 70% — consistent with single BCMA targets at comparable disease stages, but with potentially longer PFS due to reduced antigen-escape relapse.
BCMA+CD38 vs BCMA+GPRC5D: Comparison of the Two Principal Dual-Target Approaches
The two leading dual-target strategies for myeloma differ in their second target's biology, antigen co-expression profile, and clinical niche.
| Feature | BCMA+CD38 | BCMA+GPRC5D |
|---|---|---|
| Second target biology | CD38 — expressed on all plasma cells and many haematological cells; daratumumab validated the target | GPRC5D — more plasma cell-restricted than CD38; lower expression on T cells reduces fratricide risk |
| Prior CD38 antibody exposure | Most r/r myeloma patients have received daratumumab — risk of T cell fratricide (CD38 on CAR-T cells) requires consideration | GPRC5D is not targeted by any approved antibody — no prior exposure issue; CAR-T T cells do not express GPRC5D |
| T cell fratricide risk | CD38 expressed on T cells — potential for self-targeting (fratricide); managed by CD38 knockout in T cells or selection of CD38-low donors | Minimal fratricide risk — GPRC5D expression on T cells is very low |
| Antigen co-expression profile | BCMA and CD38 co-expressed on most myeloma plasma cells — dual coverage achievable on majority of disease | BCMA and GPRC5D co-expressed on myeloma; GPRC5D maintained when BCMA is lost — ideal for antigen-escape coverage |
| Clinical evidence maturity | Early trials; Chinese academic series from 2022–2024; larger datasets expected 2025–2026 | Early trials and compassionate use; GPRC5D CAR-T monotherapy data more mature; dual data accumulating |
| Best clinical scenario | Primary BCMA-naive myeloma where dual coverage is prophylactic against BCMA escape from outset | Post-BCMA failure or BCMA-low disease where GPRC5D provides an escape-proof second target |
| Regulatory status | Investigational — clinical trial access in China and early international sites | GPRC5D CAR-T monotherapy NMPA-approved in China; dual construct investigational |
Assessing Eligibility for Dual-Target Myeloma CAR-T
Dual-target eligibility assessment requires more antigen expression characterisation than single-target CAR-T — because both target antigens must be confirmed at sufficient expression level.
- 1
Confirm BCMA Expression from Recent Biopsy
BCMA expression by IHC or flow cytometry should be obtained from a biopsy performed after the most recent line of therapy — particularly if prior BCMA-directed therapy (bispecific antibody, ADC) was received. Low or lost BCMA expression after prior BCMA therapy shifts the indication toward BCMA+GPRC5D rather than BCMA+CD38.
- 2
Confirm CD38 Expression for BCMA+CD38 Products
CD38 is expressed on virtually all myeloma plasma cells — but expression level can vary, and prior daratumumab exposure may select for CD38-dim clones. Confirm current CD38 expression by flow cytometry. Additionally, assess whether CD38-knockout is required in T cell manufacturing (to prevent T cell fratricide in the infused product).
- 3
Confirm GPRC5D Expression for BCMA+GPRC5D Products
GPRC5D expression should be confirmed at the most recent disease assessment. Unlike CD38, GPRC5D testing is not yet universally standardised — CancerFax identifies which Chinese trial centres perform GPRC5D assessment as part of screening and coordinates the logistics of biopsy and testing.
- 4
Map Prior BCMA-Directed Therapy Exposure
The specific prior BCMA therapy received (cilta-cel, ide-cel, equecabtagene, teclistamab, elranatamab) affects BCMA expression status and may influence which dual-target construct is most appropriate. Document all prior BCMA therapy lines, response, and reason for discontinuation.
- 5
Identify Appropriate Dual-Target Trial or Programme
Dual-target myeloma CAR-T is primarily available through clinical trials at Chinese academic centres. CancerFax maps the patient's profile against currently enrolling trials and identifies the most appropriate protocol — minimising time to access while ensuring the most relevant construct is selected.
Single BCMA vs Dual-Target CAR-T for Myeloma: When Dual Adds Value
Dual-target constructs are not always superior to single-target BCMA CAR-T — understanding the specific clinical scenarios where dual targeting provides meaningful additional benefit guides appropriate selection.
Single BCMA CAR-T Remains Preferred
- BCMA-naive myeloma with high BCMA expression and no prior bispecificFor patients who have not received any BCMA-directed therapy, cilta-cel / equecabtagene (single BCMA) has the most mature efficacy data — 98% ORR, 78% sCR — and is the regulatory-approved standard. BCMA-high, treatment-naive to BCMA-directed therapy: single product first.
- Access and manufacturing simplicityNMPA-approved single BCMA products are available at multiple certified Chinese centres with established manufacturing pipelines. Dual-target constructs are primarily at trial centres — fewer sites, more complex logistics.
- Established long-term PFS dataCARTITUDE-1 and LUMMICAR data have 3–4 year follow-up. Dual-target constructs have 12–24 month published follow-up — insufficient to fully characterise durability.
Dual-Target Is Preferred or Indicated
- Post-BCMA therapy with retained GPRC5D expressionAfter failure of BCMA CAR-T or BCMA bispecific, BCMA+GPRC5D dual-target covers both residual BCMA-positive disease and the BCMA-negative escape fraction — the ideal scenario for dual targeting.
- BCMA-dim disease at initial assessmentWhen BCMA expression is low at baseline — suggesting a pre-existing BCMA-low subclone — dual-target products covering a second independently expressed antigen (CD38 or GPRC5D) provide better population coverage from the outset.
- Prior daratumumab-refractory disease (for BCMA+GPRC5D preference)Patients refractory to daratumumab often have CD38-dim disease — making BCMA+CD38 less attractive than BCMA+GPRC5D, where CD38 resistance does not affect the second target.
Frequently Asked Questions
Common questions from myeloma patients exploring dual-target CAR-T options.
About Dual-Target Myeloma CAR-T
I relapsed after cilta-cel — is dual-target BCMA+GPRC5D an option?
Yes — and this is one of the primary scenarios where GPRC5D-containing products (whether monotherapy GPRC5D CAR-T or dual BCMA+GPRC5D) are most relevant. Confirm BCMA and GPRC5D expression from a post-relapse biopsy. If BCMA is lost or significantly reduced, GPRC5D-containing therapy provides T cell target coverage that BCMA retreatment would not. CancerFax can identify currently enrolling GPRC5D or dual BCMA+GPRC5D trials at Chinese centres and assess your eligibility.
Is the T cell fratricide issue with CD38 a major concern?
T cell fratricide — where CD38-directed CAR-T cells attack each other or patient T cells during manufacturing — is a recognised challenge with CD38-containing constructs. Several strategies are used to mitigate it: CD38 knockout in T cells using CRISPR or RNAi, selection of CD38-low manufacturing conditions, and use of specific CD38 binding domains with lower affinity for the T cell CD38 concentration range. Chinese centres developing BCMA+CD38 constructs have specific manufacturing protocols addressing this. GPRC5D avoids this issue entirely.
Are dual-target myeloma CAR-T products more toxic than single-target?
Current early data does not suggest dual-target constructs carry substantially higher toxicity rates than single-target BCMA CAR-T. CRS and ICANS rates appear comparable. The GPRC5D-specific toxicity profile (nail and hair changes, dysgeusia) seen with GPRC5D monotherapy is expected to be present in BCMA+GPRC5D products — manageable but distinctive. Full toxicity characterisation of dual-target products is still accumulating in ongoing trials.
Is there a risk of running out of targets in myeloma?
This is a real and increasingly discussed clinical concern as myeloma therapy uses BCMA, GPRC5D, CD38, and CD138 in succession. The approach of sequencing targets — BCMA first, GPRC5D after BCMA failure, dual constructs to prevent escape — is intended to extend the target utility horizon. New targets (FcRH5, SLAMF7, NKG2D ligands, SLAM family members) are in early development specifically to provide post-GPRC5D options. CancerFax tracks the emerging target landscape and identifies trial access for patients who have exhausted commercial targets.
More from the CAR-T Cell Therapy Resource Library
Continue exploring CAR-T myeloma guides and treatment timelines.
- ↑ CAR-T Cell Therapy — Complete Guide
- Carvykti (Cilta-Cel) for Multiple Myeloma: CARTITUDE Results
- CD19 vs BCMA vs GPRC5D: What These Targets Mean
- China's Approved CAR-T Products
- The CAR-T Treatment Timeline: Leukapheresis to Discharge
- Second Opinions for CAR-T Therapy Eligibility: China vs Western Access
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Explore Dual-Target Myeloma CAR-T Access Through CancerFax
CancerFax reviews your myeloma treatment history, BCMA and CD38/GPRC5D expression, and prior CAR-T or bispecific exposure to map eligibility for dual-target CAR-T protocols at Chinese academic centres.
This content is for informational purposes only. Dual-target myeloma CAR-T is primarily investigational. Always consult a qualified myeloma specialist before making treatment decisions.